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ABSTRACT
Objectives: Copy number variants (CNVs) have been recognized as a source of genetic variation
that contributes to disease phenotypes. Alzheimer disease (AD) has high heritability for occur-
rence and age at onset (AAO). We performed a cases-only genome-wide CNV association study
for age at onset of AD.
Methods: The discovery case series (n  40 subjects with AD) was evaluated using array compar-
ative genome hybridization (aCGH). A replication case series (n  507 subjects with AD) was
evaluated using Affymetrix array (n  243) and multiplex ligation-dependent probe amplification
(n  264). Hazard models related onset age to CNV.
Results: The discovery sample identified a chromosomal segment on 14q11.2 (19.3–19.5 Mb,
NCBI build 36, UCSC hg18 March 2006) as a region of interest (genome-wide adjusted p 
0.032) for association with AAO of AD. This region encompasses a cluster of olfactory receptors.
The replication sample confirmed the association (p  0.035). The association was found for each
APOE4 gene dosage (0, 1, and 2).
Conclusion: High copy number in the olfactory receptor region on 14q11.2 is associated with
younger age at onset of AD. Neurology® 2011;76:1302–1309
GLOSSARY
AAO  age at onset; aCGH  array comparative genome hybridization; AD  Alzheimer disease; CI  confidence interval;
CN  copy number; CNV  copy number variant; DZ  dizygotic; FISH  fluorescent in situ hybridization; HR  hazard ratio;
LD  linkage disequilibrium; MLPA  multiplex ligation-dependent probe amplification; MZ  monozygotic; OR  odds ratio;
RR  relative risk; SNP  single nucleotide polymorphism.
Alzheimer disease (AD) is the most common form of dementia and leads to progressive cogni-
tive decline.1 The incidence of AD rises from 2.8 per 1,000 person-years in the 65- to 69-year
age group to 56.1 per 1,000 person-years in the older than 90 years age group.1 Heritability for
AD has been estimated from genetic epidemiologic studies. Twin studies have shown higher
concordance for monozygotic (MZ) than for dizygotic (DZ) twins: the pairwise concordance
for AD was 18.6% in MZ pairs and 4.7% in DZ pairs and the corresponding proband-wise
concordance rates were 31.3% and 9.3%.2
Age at onset (AAO) of AD is an important attribute that merits therapeutic targeting. If the
age at disease onset can be delayed by 5 years, it is estimated that the overall public health
burden of AD will decrease by one-half by 2047.3 APOE has been found to be an important
influence on AAO, and additional loci likely influence AAO of apparently sporadic AD.
Genome-wide case-control and AAO association studies using single nucleotide polymorphism
(SNP) arrays have identified candidate regions4 (www.alzgene.org); however, copy number
variant (CNV) association studies have not yet been reported in the literature.
The observation of widespread and abundant variation in the copy number (CN) of submi-
croscopic DNA segments has greatly expanded our understanding of human genetic variation.5
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CNVs confer a novel genetic marker map as-
saying association signals that are not detect-
able by SNPs.6 With the advent of microarray
technology allowing genome-wide ascertain-
ment of CNVs, disease associations have been
reported in schizophrenia, systemic lupus ery-
thematosus, and HIV susceptibility.7-9 CNVs
influence gene expression, phenotypic varia-
tion, and adaptation by altering gene dosage
and genome organization.5,9
In this study, we performed a genome-wide
CNV association study to identify loci that
modify AAO of AD.
METHODS Subject cohorts. The discovery (n  40) and
replication (n  507) cohorts met National Institute of Neuro-
logical and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association criteria for probable
AD.10 The discovery cohort was ascertained at the AD and
Memory Disorders Center of Baylor College of Medicine.11
Cases found to carry the APOE4/4 genotype were excluded from
the discovery cohort to diminish the variance in AAO caused by
the APOE4 allele. The replication dataset was ascertained as part
of the Texas Alzheimer Research Consortium project.12 Further
description of the cohorts is available in appendix e-1 and table
e-1 on the Neurology® Web site at www.neurology.org.
Standard protocol approvals, patient consents. The In-
stitutional Review Board of all participating sites approved the
study. Informed consent was obtained from each subject and
their legally authorized representative, as subjects with dementia
constitute a vulnerable population.
AAO phenotyping. AAO was determined with 2 standardized
methods in both cohorts: 1) caregiver estimate by prompted
standard question regarding onset of symptoms and 2) physician
estimate of duration of illness using a standardized and validated
structured interview with landmark event to facilitate recall.13
Detection of CN variation association with AAO. Dis-
covery cohort. The discovery study was exploratory, as there
were no available data on CNV and genome-wide association
study in AD. The post hoc power analysis for a Weibull regres-
sion using our empirical results from this study to determine a
distribution of ages and CNV states showed a power of between
40% and 60% to detect an association of this effect size for a risk
allele frequency of between 5% and 10% in a sample size of 40.
Array comparative genome hybridization (aCGH) was used
to detect genomic CN variation at a high resolution level with an
8.9-kb overall median probe spacing (Agilent Human Genome
CGH microarray 244A). The normalized log-ratio data were
generated by the manufacturer’s microarray scanner and quanti-
fication software (CGH analytics, Agilent) and were sorted by
genomic location using the NCBI build 36 (UCSC hg18 March
2006) of the human genome. The sorted data were grouped into
5-probe sliding window bins, and the mean log2 ratios for each
bin were determined for use in the subsequent analysis.
AAO was related to log2 ratio using Weibull para-
metric hazard function regression (survival package in R;
http://cran.r-project.org). The 5-probe sliding window size
was selected empirically based on extensive experience in clin-
ical CNV detection which utilizes confirmation by fluores-
cent in situ hybridization (FISH). We performed a genome-
wide correction for multiple testing by repeating the analysis
1,000 times permuting patient AAO. For each permutation
the maximum geometric mean of log p values for 20 con-
secutive bins was determined. The use of 20 consecutive bins
incorporates the dependence between the consecutive
5-probe sliding windows as well as our desire to focus on
regions that exhibit a consistent association across a genomic
region. Only 32 of 1,000 random permutations generated a
set of contiguous results where the geometric mean of p values
was as strong as that found for the 14q11.2 interval.
In order to rule out spurious association from a rare CNV
present in only one individual at the extremes of the AAO spec-
trum we calculated signal variance for each bin. We determined
the 99th percentile of these variances and we identified all re-
gions that exceeded this variance threshold (n  2,400). We
applied the 99th percentile variance filter as a second dimension
complementary to the p value for hazard regression analysis to
prioritize highly variable AAO-associated regions for replication
analysis. Furthermore, we performed segmentation analysis on
the cohort using the Agilent ADM2 algorithm to confirm that
the associations observed in the hazard analysis correspond to
actual segmental events. We required that the CNV is present in
at least 5% of the cohort (2 or more individuals).
Replication cohort. A replication cohort (n  507 subjects
with AD) was evaluated using Affymetrix array (n  243) and
multiplex ligation-dependent probe amplification (MLPA)14
(n  264) (table e-2). The replication cohort sample size was
determined based on the effect size from the discovery cohort
taking into account the variance of AAO due to the APOE4, as the
replication cohort included all APOE4 genotypes. Power analysis for
the replication study was performed using the time-to-event statisti-
cal power calculation method spower from the survival analysis util-
ity R library Hmisc (http://cran.r-project.org/). We used the
observed AAO data from the interval defined in the preliminary
data to simulate AAO values for such CNV data (1,000 replicates). For
a sample size of 350, we achieve a power of 90% in our simulations.
CN genotype for 243 patients was assayed on a Genome-
Wide Human SNP Array 6.0 (Affymetrix). The log2ratios were
generated in the Genotyping Console 3.0.1 software after re-
gional GC correction using 78 concomitantly ascertained nor-
mal controls as reference. A Gaussian mixture model was applied
to the normalized mean intensities to analyze CN state (appen-
dix e-1 and figure e-1). The CN calls were validated by MLPA
(MRC Holland) in a subset of subjects and in all subjects with
the 5 CN state (figure e-2). CN genotype for the subsequent
264 subjects was assayed by the high throughput MLPA assay.
CN calls were also made by use of a Gaussian mixture model
(appendix e-1 and figure e-1). The distribution of CN states
within the assays is depicted in table e-3.
AAO was related to the inferred CNV dosage of the 14q11.2
region detected in the discovery cohort (Variation_0316;
http://projects.tcag.ca/variation/) using Cox proportional hazard re-
gression (Survival Package in R; http://cran.r-project.org/). We in-
corporated sex, APOE4 dosage (0, 1, 2), and the interaction
between APOE4 dosage and the chromosome 14q11.2 locus CN
state as covariates into the regression model.
RESULTS QC and genotyping consistency between
platforms and FISH confirmation. QC measures are
detailed in appendix e-1. The CNVs inferred in the
replication cohort are depicted in figure 1A in the
context of previously observed variants in the Data-
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Figure 1 The genomic context of variation_0316 and genotyping accuracy
(A) The multiallelic variation_0316 (black bars) detected in 35% of the subjects in relation to known copy number variants (CNVs) (orange bars). The
genomic coordinates on chromosome 14 are expressed in Mb. The hashed red bars on the genomic coordinate line are olfactory receptor genes and the
black bars represent pseudogenes. (B) Three subjects ascertained on both the array comparative genome hybridization (aCGH) and single nucleotide
polymorphism (SNP) arrays, having 2, 3, and 4 copy genotypes in the 3 respective panels. The aCGH data are plotted by log_2 ratio and the SNP array data
are visualized as copy number state after segmentation with the HMM algorithm. Multiplex ligation-dependent probe amplification assays are shown in (C)
for 3 HapMap samples harboring 2, 3, and 4 copy genotypes (equivalent of panel B). Confirmation of gene dosage and genomic location by fluorescent in
situ hybridization using G248P88752A11 fosmid clone (green signal) and RP11–52401 control BAC clone (red) for the same 3 HapMap samples harbor-
ing 2, 3, and 4 copy genotypes are demonstrated in (D).
1304 Neurology 76 April 12, 2011
base of Genomic Variants. The sizes and location of
the CNVs detected in the replication study are in
agreement with the reported CNVs. We validated
that CN was congruent between the various assays
(Agilent Human Genome CGH microarray 244A,
Genome-Wide Human SNP Array 6.0 [Affymetrix],
and the MLPA) by genotyping a subset of samples by
2 or 3 assays (figure 1, B and C). The unique se-
quence around the OR4K2 gene allowed us to con-
firm the CNV by FISH15 (figure 1D). The FISH
suggests that up to 3 copies are located on the same
chromosome in close proximity.
Olfactory receptor cluster CN association with AAO of
AD. Discovery cohort. AAO was associated with CN
variation on chromosome 14q11.2 between 19.2 and
19.49 MB (NCBI build 36, UCSC hg18 March 2006):
22 consecutive results had a loge p value of 7 or more
(figure 2A and table e-4) (multiple testing corrected p 
0.032). This region also had high log2 ratio variability
(top 1%) and segmentation confirmed CNV calls at an
allele frequency over 5% (figure 2B). The array data
heat map for the region (figure 2C) visually illustrates
that higher CN (yellow) is associated with earlier AAO
(figure 2C). A 10-year difference in median AAO—67
years vs 77 years—was found when comparing high to
low CN partitioned cohort (normalized mean log2 ra-
tio 0 vs 0).
The interval includes a multiallelic cluster of over-
lapping CNVs with various breakpoints (figure 1A
and figure e-2). The association signal comes from
olfactory receptor gene cluster in the region where
OR4M1, OR4N2, OR4K2, OR4K5, and OR4K1 are
located. The summary test statistics (Weibull model)
for the region are summarized in table 1. The com-
plete set of hazard function outcomes with log_e
p  7 depicted in the Manhattan plot are summa-
rized in table e-4. The chromosome 14q11.2 region
is the only region that survived multiple testing cor-
rection and fulfilled our a priori significance filter
settings (allele frequency 5% and variance in
99th percentile).
Replication cohort. The Cox proportional hazard
analysis confirmed the association of CNV varia-
tion_0316 dosage on chromosome 14q11.2 with
AAO of AD (p  0.03) in the replication cohort
(tables 1 and 2). The analysis also replicated signifi-
cant AAO association of APOE 4/4 reported in the
literature. No interaction between APOE and the
CN locus was identified by the regression; no gender
effects were detected. The dosage association of the
olfactory receptor gene cluster on AAO of disease is
presented in the box plot (figure 3A). The time to
event survivorship curves for the various CN states
depicts the percentage of subjects diagnosed by age
for each CN state (figure 3B). The relative risk
(RR) for onset of AD is proportionally increased
1.12-fold for each one-copy increase of the olfac-
tory receptor CN state (table 1). The association
of the 14q locus appears to be independent of and
in addition to the effect of APOE.
The most striking association signal appears to
originate from the 5 CN state on all APOE back-
Figure 2 Variation_0316 association with age at onset (AAO) of Alzheimer
disease in the discovery cohort
The discovery study is summarized in figure 2. The –loge p values for Z scores from the
hazard function regression performed on the array data using a 5-probe sliding window are
plotted as a function of genomic location (A). In panel B, the –loge p values are plotted
against the variance (surrogate for allele frequency and number of alleles). The variance
filter serves to exclude spurious association from a rare copy number variant not highly
observed in the cohort and present in only one or a few individuals at the extremes of the
AAO spectrum (B). (C) Age information and array data for AAO is represented in the red and
blue color bar to the side of each array data heat map. Each cell in the subject age bar is
adjacent to the row of the array data heat map for that subject. Red represents younger
subjects, while blue represents older subjects in a linear scale from age 55 to age 84. The
blue and yellow heat maps convey copy number array data for the region. Each blue-yellow
row represents a subject and each column represents the data for a single oligonucleotide
probe. Genomically adjacent oligos are shown next to each other from left to right.
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grounds; the 2 copy and 3 copy states have similar
AAO and the 4 copy state has a trend toward earlier
AAO on all APOE4 backgrounds. We built an addi-
tional Cox proportional hazard model (categorical)
treating the 2, 3, and 4 copy states as a single class
and the 5 state as the other CN class based on this
observation. The 5 CN subjects were 2 times more
likely to be diagnosed with AD by any given age
compared to the 2, 3, and 4 copy carriers (RR 
2.05, confidence interval [CI] 1.33–3.18, p  0.001)
(table 1). The risk of onset before age 72 years (me-
dian in the entire sample) for persons who had CN of
5 or more was 6-fold higher compared to persons
having lower CN (hazard ratio [HR]  5.8, 95% CI
1.7–20). The risk for APOE4/4 subjects was 4-fold
higher compared to other APOE genotypes (HR 
4.1, 95% CI 2.3–7.6).
The inclusion criteria aimed to capture a broad
range of AAO to increase power which potentially
resulted in enrollment of early-onset familial AD
cases. We did not screen the cohort for mutations in
APP, PSEN1, and PSEN2 as cohort studies have
demonstrated that mutations in these genes are sel-
dom detected in patients who do not have an auto-
somal dominant family history of AD. However, in
order to further confirm the association, we reana-
lyzed the subset of the replication cohort with AAO
over 60. The olfactory receptor locus remained asso-
ciated with AAO in the categorical model (RR 
1.72, CI 1.01–2.96, and p  0.049) in the reduced
dataset (n  439).
In the Affymetrix set (n  243) we used the com-
plete SNP dataset ascertained from the Genome-
Wide Human SNP Array 6.0 (Affymetrix) to assess
the possibility of population substructure confound-
ing CN state. The population substructure analysis
was performed by principal component analysis with
the Eigenstrat package for the first 10 principal com-
ponents.16 The projected values for the samples were
then plotted against each other for the first 2 compo-
nents (figure e-3).
DISCUSSION AD is one of the most significant
public health problems and likely to increase in its
burden to society, considering projected increases in
longevity and number of aging individuals.1 Delay of
AAO of AD could result in marked decrease in prev-
alence and therefore AAO is an important attribute
of disease and a desired therapeutic target. Although
AAO can only be estimated, the usefulness of deter-
mining symptom onset via the single question in-
quiry method has been demonstrated by the
identification of the influence of the APOE4 allele on
AAO.17 We estimated AAO by 2 methods, the single
question inquiry and a validated structured interview
with landmark event to facilitate recall of the surro-
gate historian.13 The Spearman correlation of the 2
methodologies was significant (Spearman correlation
rho  0.9409, p  2.2  1016; CI 0.90–0.97) and
outlier and residual analysis showed no systematic
deviation between the 2 methods.
We have undertaken a cases-only CN variation
genome-wide association study with AAO of AD and
have detected association of gene dosage of the olfac-
tory receptor region on chromosome 14q11.2 with
AAO of AD. The replication cohort confirmed the
association. Moreover, this analysis showed the CN
association to be independent of and in addition to
the association observed for APOE4. The CNV con-
tributing to the association signal harbors an olfac-
Table 1 Variation_0316 dosage association with AAO of AD: Weibull hazard
outcome in the discovery set and Cox proportional hazard
outcomes in the replication cohort
Cohort Model Variable p Value
Relative
risk 95% CI
Discovery Dosage CN 0.0005153 2.117 1.386–3.232
Replication Dosage CN 0.0346015 1.124 1.008–1.252
Replication Dosage E4/4 1.25E–09 2.407 1.813–3.195
Replication Categoricala CN 0.0045201 1.938 1.228–3.061
Meta-analysis Dosage CN 0.0092225 1.149 1.035–1.276
Meta-analysis Dosage E4/4 2.55E–09 2.322 1.76–3.063
Meta-analysis Categoricala CN 0.0012671 2.053 1.326–3.179
Abbreviations: AAO  age at onset; AD  Alzheimer disease; CI  confidence interval; CN 
copy number.
a Categorical model: the data suggest that the 5 CN state represents the highest risk. We
applied a categorical model (category 1 includes 2, 3, and 4 CN states, category 2 the 5
CN state) to estimate the risk for the 5 state.






CN APOE4 Median Mean SE Range
2 N/N 80 73.5 73.19 1.17 48–98
N/4 110 73 71.95 0.74 52–89
4/4 29 65 66.55 1.4 48–80
3 N/N 78 76 73.04 1.07 47–86
N/4 80 74 72.11 0.95 51–89
4/4 26 69 69.21 1.4 50–86
4 N/N 28 69 69.33 2.06 52–90
N/4 47 72 71.33 1.22 49–90
4/4 9 66 65.73 1.53 58–73
5 N/N 2 65.5 65.5 0.5 65–66
N/4 13 67 66.35 2.43 53–83
4/4 5 58 62 3.91 55–76
Abbreviations: AAO  age at onset; CN  copy number; CNV  copy number variant.
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tory receptor gene cluster, which contains plausible
candidate modifier genes in disease pathomechanism
in agreement with clinical and neuropathologic ob-
servations. The allele frequencies of the CNV region
identified are comparable to prior reports,18 and the
allele frequencies in the replication study are consis-
tent with detection of the association between CN
and AAO in the discovery cohort. Applying a cate-
gorical model to the replication dataset yielded a
more significant association, suggesting that the 5
CN state confers the highest risk.
Although we detected all CN states in the con-
trols as well (table e-5), the sample size is small and
the study is not designed for case-control association.
In fact, our study design is statistically powerful
because the cases-only approach eliminated the mis-
classification bias in this late-onset disease with age-
dependent penetrance. However, the cases-only
design is a limitation of our study. Sample size calcu-
lations for a case-control association based on an al-
lele frequency of 0.04 (the observed frequency of
CN5 high risk state) and using an estimated odds
ratio (OR) of 1.5 (effect size for the CN5 state)
suggest that a sample size of 1,800 cases and 1,800
controls are required to achieve a power of 0.8 to
detect an association. This sample size is beyond the
scope of this study.
Previous studies19-21 investigating the genetics of
AAO of AD used SNP datasets, and thus our CNV
approach is complementary to these studies. The
prior SNP association studies are likely to have
lacked sensitivity to detect this locus because of its
Figure 3 Variation_0316 association with age at onset (AAO) of Alzheimer disease (AD) in the
replication cohort
(A) Box plots depict the dosage association of the inferred copy number variant (CNV) variation_0316
(http://projects.tcag.ca/variation/) with AAO. There is an association of increased CN state with earlier AAO, the largest
association signal emerging from the CN state 5. (B) The corresponding survivorship curves for each of the groups de-
picted in the box plots. Subsequently, Cox proportional hazard regression was performed using the inferred CNV varia-
tion_0316 incorporating APOE and gender into the model. (C) Box plots show the dosage association with AAO, this time
separating against the various APOE backgrounds. In each APOE class increased CN state is associated with earlier AAO,
again the largest signal emerging from the CN state 5. The time to event curves in (D) contrast the CN2 and CN3 states
(red) with the CN5 states (green) on the APOE N/4 (light) and APOE 4/4 (dark) backgrounds.
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complex allelic structure. While the ability of SNPs
to tag CNVs is debated,22 loci with multiple types of
alleles with rare individual allele frequencies are likely
less amenable to SNP tagging. We performed the
Cox proportional hazard regression on 148 SNPs
flanking the CNV locus using additive, recessive, and
dominant models with the assumption that if SNPs
are in linkage disequilibrium (LD) with the CNV we
would detect the association (table e-6 and fig-
ure e-4). Only one SNP (rs11849055) reached
Bonferroni-corrected significance in the recessive
model, and this SNP is not in LD with the CNV we
detected. Our results may suggest that the observed
CNV events likely occurred on various SNP haplo-
types as independent events.
This study shows an association of CN varia-
tion_0316 and AAO, and does not lead us to causal
genes per se. However, the association signal arising
from a multiallelic CNV locus and the gene dosage
association suggest that the gene content of the CNV
including the olfactory receptor cluster is a potential
modifier of AAO in AD. Prospective cohort studies
established the risk olfactory deficit confers for the
development of cognitive decline. A prospective
study of 1,920 cognitively normal subjects found a
significant association between olfactory impairment
at baseline and 5-year incidence of cognitive impair-
ment (OR  6.62, CI  4.36–10.05).23 Another
study of 1,604 older adults without dementia found
that women with anosmia who possessed at least one
APOE4 allele had an OR of 9.71 for development of
cognitive decline over the ensuing 2 years, compared
with an OR of 1.9 for women with no olfactory dys-
function and at least one such allele.24 Neuropatho-
logic series have found marked cell loss in the
olfactory bulb and anterior olfactory nucleus and the
presence of disease-related pathology: neuritic
plaques and neurofibrillary tangles in these struc-
tures.25 Whether loss of olfaction is a primary or sec-
ondary phenomenon in the pathomechanism of AD
is unclear; however, this genetic observation raises
the possibility for its role in modifying the AAO.
Although the allele frequency is low, in a disease
with a prevalence of 5.3 million a frequency of 4%
translates to over 200,000 subjects with the high CN
state affected by the disease. Patients with AD with
the earliest AAO represent the most desired group for
intervention with disease-modifying therapy. Patho-
genic CNVs may be more amenable to therapy than
other types of genetic variation. In contrast to muta-
tion events resulting in loss of function or toxic gain
of function, CNVs alter gene dosage, allowing mod-
ification by small molecules which may offset the
dosage effects.26 For example, the CMT1A duplica-
tion rat model treated with a progesterone antagonist
achieved clinical and pathologic improvement even
by partial correction of gene expression by epigenetic
modification.27 If confirmed, evaluation of olfactory
receptor CN may lead to both earlier detection and
potential disease-modifying therapy, both of which
could have a major impact on the public health bur-
den of AD.
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